Cynvenio Biosystems, Inc. Announces ClearID, a Breakthrough Test for Monitoring Breast Cancer Patients and Early Detection of Recurrence
10/3/2013 10:17:50 AM
LOS ANGELES--(BUSINESS WIRE)--Cynvenio, a cancer diagnostics company focused on transforming cancer treatment and management through the molecular analysis of tumor biomarkers in blood, today launched a new weapon in the fight against breast cancer, the ClearID Breast Cancer monitoring program. ClearID Breast Cancer is a high-tech monitoring program that enables the early detection of breast cancer recurrence – a valuable tool that empowers patients to defend their health by actively monitoring for recurrence.
Help employers find you! Check out all the jobs and post your resume.
comments powered by